Short-chain fatty acids enhance muscle mass and function through the activation of mTOR signalling pathways in sarcopenic mice.

Chaoran Liu, Pui Yan Wong, Qianjin Wang, Hei Yuet Wong, Tao Huang, Can Cui, Ning Zhang, Wing Hoi Cheung, Ronald Man Yeung Wong

Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China. · pubmed

Paper

Abstract

Sarcopenia is a prevalent muscle disorder in old people leading to higher fracture rate, mortality, and other adverse clinical outcomes. Evidence indicates that short-chain fatty acids (SCFAs), which are beneficial gut microbial metabolites, were reduced in old people with sarcopenia. This study aimed to determine whether the use of SCFAs as a supplement can be a therapeutic strategy of sarcopenia in a pre-clinical model.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses sarcopenia, a condition associated with aging, and investigates the potential of short-chain fatty acids (SCFAs) as a therapeutic strategy. While it contributes to understanding a specific age-related condition, it does not tackle the root causes of aging or lifespan extension directly. The findings may have some relevance to improving muscle health in older adults, but the overall impact on the broader field of longevity research is limited.

Author of this paper? Send a correction.